Furthermore, Rituximab (an anti-CD20 monoclonal antibody), which improves xerostomia in patients suffering from Sjögren’s syndrome and induces complete remission of lymphoma in some cases [92,93], increased AQP5 expression at the apical membrane of salivary gland acinar cells [93]. Here, AQP5 is linked to xerostomia.